Skip to main content

Advertisement

Table 3 Base case results

From: Cost-effectiveness of malaria preventive treatment for HIV-infected pregnant women in sub-Saharan Africa

Country and strategy Costs per 10,000 women (USD) DALYs per 10,000 women Incremental cost Incremental DALYs averted ICER
Ghana
 2-IPT Lowa 359,992 12,055    
 3-IPT Low 360,340 11,912 348 143 Dominatedb
 3-IPT High 361,594 11,434 1602 621 Dominated
 CTX 361,009 9312 1017 2743 $0.37
Malawi
 2-IPT Lowa 393,772 14,671    
 3-IPT Low 394,744 14,563 972 108 Dominatedb
 3-IPT High 399,172 12,382 5400 2289 Dominated
 CTX 396,580 11,317 2808 3354 $0.84
Kenya
 2-IPT Lowa 383,217 7000    
 3-IPT Low 384,314 6934 1097 66 Dominatedb
 3-IPT High 388,568 6183 5351 817 Dominated
 CTX 386,518 5339 3301 1661 $1.99
Mozambique
 2-IPT Lowa 406,628 16,424    
 3-IPT Low 409,130 16,022 2502 402 Dominated
 3-IPT High 409,367 15,997 2739 427 Dominated
 CTX 404,816 15,240 −1812 1184 Cost-saving
Tanzania
 2-IPT Lowa 367,892 4364    
 3-IPT Low 370,519 4327 2627 37 Dominatedb
 3-IPT High 371,468 4231 3576 133 Dominated
 CTX 371,154 3516 3262 848 $3.85
  1. CTX cotrimoxazole, DALY disability-adjusted life year, ICER incremental cost-effectiveness ratio (cost per DALY averted) compared to the strategy in the row above, IPT intermittent preventive treatment with sulfadoxine–pyrimethamine
  2. aReference Strategy
  3. bDominated by extended dominance: a linear combination of two other strategies yields greater benefit at equal cost